Biostimulator Complications: Recognizing and Managing Them

A collagen biostimulator is generally well tolerated, but it is not free of complications. Some are expected and go away on their own, others call for follow-up and a few, rare ones, are emergencies. What sets a biostimulator apart from hyaluronic acid is a simple fact: there is no enzyme that dissolves it. That changes the weight of prevention and how almost everything that goes wrong is managed.

This guide is an overview, at a review level, to recognize each complication and organize the first response. It gives no doses, dilutions or medication protocols. Nodules, the most common late complaint, have their own guide in nodules after biostimulator; here they appear only in summary, to complete the map.

Which complications can happen?

Complications described with injectable biostimulators, such as calcium hydroxyapatite, poly-L-lactic acid and polycaprolactone, can be organized by when they tend to appear:

The timeframes are approximate and vary with the product, the area and the patient. What helps most to tell the pictures apart is crossing the time of onset with the presence or absence of inflammatory signs.

Swelling and bruising: when is it just what is expected?

Swelling and tenderness in the first days are common, especially with products applied with a larger volume of vehicle. With poly-L-lactic acid, part of the initial volume is water from the vehicle and is lost in the following days, which the patient sometimes interprets as "the product disappeared." With hydroxyapatite, there is a greater immediate volume effect. The patient's question about this is answered in does a biostimulator swell the face?.

What falls outside the expected:

• swelling that increases after the second or third day, instead of fading;
• localized swelling that is warm and painful;
• a large, tense bruise that grows in the first hours.

In these cases, the patient needs to be seen, not just advised by message.

What about asymmetry?

Asymmetry after a biostimulator usually has three origins: a prior facial asymmetry that was not recorded, uneven swelling between the sides or a different distribution of the product. Because the stimulating effect is gradual, judging the result in the first weeks tends to lead to wrong conclusions.

The usual approach is to wait for the swelling to subside, compare with the before photos in the same framing and only then decide whether any adjustment is needed in planning the next sessions. Trying to correct early asymmetry with more product, without waiting, increases the risk of excess and nodules.

Nodules and granuloma: the summary

Nodules are the best-known late complication of biostimulators. In summary:

• Non-inflammatory nodules usually have a technique or indication explanation: superficial product, a very mobile area, accumulation at one point, preparation outside the manufacturer's instructions.
• Early inflammatory nodules suggest infection until proven otherwise.
• Late inflammatory nodules raise the hypothesis of a granulomatous foreign-body reaction or biofilm, and usually call for investigation with imaging and joint management.

Classification, investigation and the approaches described are detailed in nodules after biostimulator.

When should you think of infection?

Infection can appear in the first days, as a direct consequence of the injection, or late, associated with biofilm. The classic signs are increasing pain, warmth, redness, hardening, fluctuance and, sometimes, fever and malaise.

Prevention involves rigorous skin antisepsis, clean technique, intact skin at the site and attention to active sources of infection. The advice to postpone the injection in the presence of an active infection on the face, including dental ones, usually appears in the recommendations.

Vascular occlusion with a biostimulator: what changes?

Any injectable can enter a vessel or compress it, and a biostimulator is no exception. The signs are the same as described for hyaluronic acid: sudden blanching or pallor, disproportionate pain, violet net-like discoloration, slow capillary refill and, in the following hours, darkening and blisters in the territory of an artery. The concept is in the glossary entry vascular occlusion.

The difference is in the response. With hyaluronic acid, hyaluronidase breaks down the product. With hydroxyapatite, poly-L-lactic acid or polycaprolactone, there is no agent that dissolves the material inside the vessel. The measures described in the literature for these cases aim to improve perfusion and limit damage, and the evidence is more limited. When the product combines hyaluronic acid with another substance, the enzyme can act on the hyaluronic acid part, but not on the rest.

This explains why prevention weighs even more with biostimulators: knowing the areas of highest vascular risk, choosing the instrument and plane carefully, using volumes consistent with the instructions for use and watching the skin throughout the injection.

What goes into the initial management, at a review level?

Whatever the complication, the first response usually follows an order:

1. Classify the picture by time of onset and by inflammatory or vascular signs.
2. Rule out emergencies: vascular occlusion, infection with systemic signs, visual or neurological changes.
3. Retrieve the patient record: product, lot, area, date, amount, instrument.
4. Photograph in the same standard as the before photos.
5. Consider imaging, such as ultrasound, to locate the material in nodules and late presentations.
6. Define the approach and follow-up, with referral or joint management when the picture goes beyond your field.
7. Record everything and keep a channel of contact open with the patient.

The choice of drug, route, dose and duration are individual clinical decisions, made by the qualified professional within what the rules of their professional council in Brazil allow.

How do you prevent the most common complications?

The difference between the products, which influences some of these choices, is in hydroxyapatite vs poly-L-lactic acid. The medical history in HOF has the questions that matter most before any injectable.

How do you talk to the patient?

Before the injection, the patient needs to know that a biostimulator is not reversed by an enzyme, that the result is gradual and that nodules, including late ones, are a possibility. This should be in the informed consent. A starting point for the document is the consent form template for biostimulators.

And in Harmy?

Harmy does not simulate complications or the gradual effect of a biostimulator: the projection shows the volume change in the marked areas, with the ml for each one. History stores the front photo of each session, and "Add actual result" saves the follow-up photo aligned by the eyes, which helps compare asymmetries and changes over time. It is an illustrative simulation, not a promise of results.

Checklist for biostimulator complications

1. Written protocol for vascular occlusion, infection and allergic reaction in the office.
2. Product, lot, area and amount recorded at each session.
3. Standardized photos before each injection.
4. Patient counseled in writing on what to expect and the warning signs.
5. Follow-up scheduled and contact channel defined.
6. Picture classified by timing and signs before any management.
7. Referral or joint management in severe, late or recurring cases.